S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:IPHA

Innate Pharma Competitors

$4.30
-0.09 (-2.05 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.25
Now: $4.30
$4.46
50-Day Range
$4.09
MA: $4.43
$4.83
52-Week Range
$3.30
Now: $4.30
$8.23
Volume6,078 shs
Average Volume57,402 shs
Market Capitalization$339.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Innate Pharma (NASDAQ:IPHA) Vs. ATRA, ALEC, IMVT, PCVX, CHRS, and MESO

Should you be buying IPHA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Innate Pharma, including Atara Biotherapeutics (ATRA), Alector (ALEC), Immunovant (IMVT), Vaxcyte (PCVX), Coherus BioSciences (CHRS), and Mesoblast (MESO).

Atara Biotherapeutics (NASDAQ:ATRA) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider and Institutional Ownership

2.1% of Innate Pharma shares are owned by institutional investors. 4.3% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Atara Biotherapeutics and Innate Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
Innate Pharma03102.25

Atara Biotherapeutics currently has a consensus target price of $35.8750, indicating a potential upside of 125.77%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Innate Pharma.

Profitability

This table compares Atara Biotherapeutics and Innate Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
Innate PharmaN/AN/AN/A

Earnings & Valuation

This table compares Atara Biotherapeutics and Innate Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.80
Innate Pharma$96.12 million3.53$-23,250,000.00($0.34)-12.65

Innate Pharma has higher revenue and earnings than Atara Biotherapeutics. Innate Pharma is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Innate Pharma beats Atara Biotherapeutics on 6 of the 11 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider and Institutional Ownership

61.5% of Alector shares are owned by institutional investors. Comparatively, 2.1% of Innate Pharma shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Alector and Innate Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alector-757.78%-53.86%-31.44%
Innate PharmaN/AN/AN/A

Earnings & Valuation

This table compares Alector and Innate Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.22 million60.94$-105,390,000.00($1.71)-9.50
Innate Pharma$96.12 million3.53$-23,250,000.00($0.34)-12.65

Innate Pharma has higher revenue and earnings than Alector. Innate Pharma is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alector and Innate Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alector00603.00
Innate Pharma03102.25

Alector currently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Alector's stronger consensus rating and higher probable upside, analysts clearly believe Alector is more favorable than Innate Pharma.

Summary

Alector beats Innate Pharma on 7 of the 13 factors compared between the two stocks.

Immunovant (NASDAQ:IMVT) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Insider & Institutional Ownership

40.2% of Immunovant shares are owned by institutional investors. Comparatively, 2.1% of Innate Pharma shares are owned by institutional investors. 0.2% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Immunovant and Innate Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunovantN/A-34.80%-32.38%
Innate PharmaN/AN/AN/A

Earnings and Valuation

This table compares Immunovant and Innate Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A$-66,390,000.00($1.54)-8.49
Innate Pharma$96.12 million3.53$-23,250,000.00($0.34)-12.65

Innate Pharma has higher revenue and earnings than Immunovant. Innate Pharma is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Immunovant and Innate Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunovant011402.93
Innate Pharma03102.25

Immunovant currently has a consensus target price of $45.60, indicating a potential upside of 248.62%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Immunovant's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunovant is more favorable than Innate Pharma.

Summary

Immunovant beats Innate Pharma on 6 of the 11 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Insider & Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 2.1% of Innate Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Vaxcyte and Innate Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/AN/AN/A
Innate PharmaN/AN/AN/A

Earnings and Valuation

This table compares Vaxcyte and Innate Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-50,270,000.00N/AN/A
Innate Pharma$96.12 million3.53$-23,250,000.00($0.34)-12.65

Innate Pharma has higher revenue and earnings than Vaxcyte.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vaxcyte and Innate Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
Innate Pharma03102.25

Vaxcyte currently has a consensus target price of $48.00, indicating a potential upside of 103.22%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Vaxcyte is more favorable than Innate Pharma.

Summary

Vaxcyte beats Innate Pharma on 4 of the 6 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Insider & Institutional Ownership

2.1% of Innate Pharma shares are owned by institutional investors. 15.9% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Coherus BioSciences and Innate Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Coherus BioSciences33.06%90.98%27.33%
Innate PharmaN/AN/AN/A

Earnings and Valuation

This table compares Coherus BioSciences and Innate Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$356.07 million3.12$89.83 million$1.2312.39
Innate Pharma$96.12 million3.53$-23,250,000.00($0.34)-12.65

Coherus BioSciences has higher revenue and earnings than Innate Pharma. Innate Pharma is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Coherus BioSciences and Innate Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Coherus BioSciences01502.83
Innate Pharma03102.25

Coherus BioSciences currently has a consensus target price of $27.8571, indicating a potential upside of 82.73%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Coherus BioSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Coherus BioSciences is more favorable than Innate Pharma.

Summary

Coherus BioSciences beats Innate Pharma on 11 of the 13 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Insider & Institutional Ownership

2.8% of Mesoblast shares are owned by institutional investors. Comparatively, 2.1% of Innate Pharma shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Mesoblast and Innate Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-591.00%-18.69%-13.85%
Innate PharmaN/AN/AN/A

Earnings and Valuation

This table compares Mesoblast and Innate Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million33.54$-77,940,000.00($0.74)-12.41
Innate Pharma$96.12 million3.53$-23,250,000.00($0.34)-12.65

Innate Pharma has higher revenue and earnings than Mesoblast. Innate Pharma is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Mesoblast and Innate Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast13202.17
Innate Pharma03102.25

Mesoblast currently has a consensus target price of $14.55, indicating a potential upside of 58.50%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Innate Pharma is more favorable than Mesoblast.

Summary

Innate Pharma beats Mesoblast on 8 of the 13 factors compared between the two stocks.


Innate Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.